key: cord-0068495-nst5d629
authors: Hergenroeder, G.; Cogen, J.; Genatossio, A.; McNamara, S.; Pascual, M.; Hernandez, R.
title: 25: Seroprevalence and clinical characteristics of SARS-CoV-2 infection in children and adolescents with cystic fibrosis
date: 2021-10-15
journal: J Cyst Fibros
DOI: 10.1016/s1569-1993(21)01450-8
sha: f3ab351410cdbb6f023a244a486ba19aace36c3b
doc_id: 68495
cord_uid: nst5d629

nan

Background: People living with CF (PwCF) often experience high physical and emotional symptom burden. Yet it is unclear whether caregivers and clinicians similarly perceive the specific symptoms and the distress they cause PwCF. Methods: Parallel online surveys were developed and distributed to adults with CF, caregivers of PwCF, and clinicians recruited from the CFF Community Voice listserv, CFF care team listservs, and through social media posting. Participants provided demographics and completed a modification of the Supportive Care Needs Survey-34, which assesses 34 symptoms commonly experienced in serious illness. Respondents were also asked to describe barriers to symptom management. Chi-square tests were used to compare responses between groups. Results: N = 62 PwCF, 30 caregivers, 175 clinicians. All groups included cough (61% of PwCF, 60% of caregivers, 77% of clinicians), shortness of breath/breathlessness (55%, 50%, 75%), fears about CF getting worse (55%, 47%, 71%) and anxiety/worrying (53%, 47%, 75%) in the top 10 symptoms experienced by PwCF. PwCF uniquely included feeling bloated (60%) and diarrhea (55%) as top 10 symptoms experienced. Caregivers uniquely listed lack of appetite (57%) and constipation (57%), and clinicians uniquely listed depressed feelings/feeling sad (74%), feelings about death and dying (72%), weight loss (71%), wheezing/chest tightness (71%), and uncertainty about the future (71%) as top 10 perceived symptoms. PwCF listed pain most often (56%) as a symptom causing distress, whereas caregivers listed difficulty sleeping (47%) and clinicians listed shortness of breath and depressed feelings (69%) most often as symptoms causing distress. PwCF ranked pain as a symptom experienced more often than caregivers, though this difference was not statistically significant (68% vs 50%, P = 0.10). Clinicians ranked pain as a symptom experienced more often than caregivers (69% vs 50%, P = .04) and more often causing distress than did caregivers (69% vs 40%, P = .01). PwCF, caregivers, and clinicians differed in their likelihood to endorse pain as distressing for PwCF (56% vs 40% vs 65%, P = .03). Barriers to pain management as expressed by PwCF included perceptions of clinician disregard for pain distress (e.g., "your pain can't be that bad…"), fears of stigmatization (e.g., "…and then blamed as being an addict…"), and having limited options for pain management (e.g., "[my] CF clinic is not interested in doing [pain management] and acts like a palliative referral is inappropriate"). Conclusion: Caregiver and clinician perceptions of the most common, and most distressing, symptoms related to CF differ substantively from those reported by PwCF. Further, PwCF describe perceptions of diminishing and discriminatory behaviors that may lead to unmet symptom needs. Practice guidelines for symptom management for PwCF should reflect the variety of symptoms most common and distressing for PwCF. Research is needed to explore and address barriers to symptom management and alleviate pain stigmatization within the CF community. Acknowledgements: The authors would like to thank the Cystic Fibrosis Foundation for facilitating research through Community Voice to support this work. Additionally, we would like to thank all the adults with cystic fibrosis and family members across the United States who participated for sharing their insights. (COVID-19) , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first detected in the United States in January 2020. Although pediatric cases represent a small proportion of total infections in the United States (11.8%), the majority of hospitalized children have underlying medical conditions, with chronic lung disease being most common. To date, only 1 study has described the clinical manifestations of COVID-19 specifically in children with CF [1] . Our study aims to define the rates of symptomatic and asymptomatic infection in people with CF (PwCF) followed at a large pediatric CF center and to assess demographic and clinical characteristics associated with infection. Methods: All children with CF followed at Seattle Children's Hospital CF Center were eligible to enroll between July 20, 2020 and February 28, 2021. Participants or parents completed an intake survey, including demographic data, COVID-19 exposures, and information about viral/respiratory illnesses after February 1, 2020. SARS-CoV-2 serostatus was determined with a commercial assay for nucleocapsid IgG. Participants or parents were sent weekly questionnaires electronically asking about exposures to and symptoms of COVID-19 for the 12-month study enrollment period. Follow-up serology testing occurs at 6-and 12-months post-enrollment. Results: Of 125 participants, 8 had positive SARS-CoV-2 antibodies (6.4%). Five were positive on enrollment, and 3 additional PwCF were positive at 6month follow-up with testing of 38 participants to date. Among all participants, the average age at enrollment was 11.5 years (range 0-20), 49% were female, and 92% were pancreatic insufficient. Ninety percent of participants had 1 or 2 copies of Phe508del CFTR mutation. The median baseline FEV1pp was 104% (IQR 98-115, N = 98). Among the 8 positive cases, 4 endorsed mild upper respiratory infection (URI) symptoms prior to testing, and the remainder were asymptomatic. While only 10% of all participants identify as Hispanic, among PwCF who were seropositive, 50% (4/8) identify as Hispanic (P = 0.002). Among positive participants, 2 have had repeat serology testing, and both continue to have positive SARS-CoV-2 serologies 18-25 weeks later. Conclusion: Our data suggest that a majority of PwCF have mild to no symptoms of COVID-19 when infected. PwCF who identify as Hispanic appear to be disproportionately affected, consistent with data describing racial and ethnic disparities among patients with COVID-19 in general. Initial 6-month follow-up testing suggests antibody durability but will require further investigation.

Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study

Caregiver depression and anxiety prevalence in cystic fibrosis: A systematic review and meta-analysis investigating epidemiology L. Lord 1 , D. McKernon 2 , L. Grzeskowiak 3 , S. Kirsa 4

College of Medicine and Public Health

Previous studies show caregivers of people with cystic fibrosis (CF) are at high risk of depression and anxiety, which can negatively affect CF outcomes